Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Strong Dollar Remains Headache For Johnson & Johnson

The continued climb of the U.S. dollar weighed heavily on pharmaceutical giant Johnson & Johnson’s first quarter earnings reported Tuesday morning. It was in many ways a repeat of a quarter earlier — only this time the numbers were worse with currency woes cutting further into international sales, profitability and now the company’s outlook on the coming […]

Read More »

Physicians Hail Senate Passage Of ‘Doc Fix’ As Value-Based Care Takes Hold

The U.S. Senate, following last month’s bipartisan action by the U.S. House of Representatives, tonight overwhelmingly passed a repeal of Medicare’s controversial sustainable growth rate formula. The vote, by a whopping 92-8 vote in the Senate, will avert a 21 percent cut in Medicare payments to doctors while at the same time moving future reimbursement […]

Read More »

How Obamacare Cost Squeeze May Push Rite Aid To Walgreens

Italian billionaire Stefano Pessina wasn’t ready this week to say Walgreens Boots Alliance (WBA) was prepared to buy Rite Aid (RAD), but he said more government influence on payments to pharmacies could spur rapid consolidation in the U.S. Now the top executive at Walgreens, Pessina speaks from experience having run Alliance Boots pharmacies in Europe […]

Read More »

Health data breaches on the rise

Large-scale health data breaches reported by doctors and health plans have been rising steadily, a new report shows. From 2010 to 2013, nearly 1000 large breaches affected more than 29 million individual health records, and more than half resulted from theft or loss of laptops, thumb drives and paper records, according to researchers with access […]

Read More »

Three Biotechs Well-Positioned for M&A: Gilead, Celgene, and Biogen

April 14, 2015By Riley McDermid, Breaking News Sr. Editor The American biotech sector will see a continued boom in its merger and acquisition cycle after an unprecedented first quarter saw over $100 billion in deals, with companies like Gilead Sciences, Inc. (GILD), Celgene Corporation (CELG), and Biogen, Inc. all poised to participate, said UBS […]

Read More »

BioRestorative Shutters Florida Office and Opens New HQ and Lab in New York

April 14, 2015By Alex Keown, Breaking News Staff MELVILLE, N.Y.– BioRestorative Therapies, Inc. a life sciences company developing adult stem cell-based therapies for various medical applications, moved its corporate and laboratory operations to Long Island from Jupiter, Fla., the company announced this morning. In 2014 BioRestorative Therapies (BRT) was awarded $500,000 in tax credits […]

Read More »

Merck & Co. Execs See Big Compensation Increases

April 14, 2015By Mark Terry, Breaking News Staff Kenilworth, N.J.-based Merck & Co. (MRK)’s recent Securities and Exchange Commission (SEC) filings indicate that CEO Kenneth Frazier will see an increase in total compensation of about 87 percent this year. In addition, Robert Davis, company chief financial officer, will see an increase of about 10 […]

Read More »

Incyte Targets Switzerland for a New Clinical Development HQ

April 14, 2015By Krystle Vermes, Breaking News Staff Delaware-based Incyte Corporation (INCY), an oncology-focused biopharmaceutical company, announced on April 14 that it will be establishing a European headquarters in Geneva, Switzerland. Incyte Europe S.a.r.l., as it has been titled, will conduct European clinical development operations. It will occupy approximately 9,000 square feet by mid-2015. […]

Read More »

The CementBloc welcomes 3 new creative leaders to its award-winning team

NEW YORK, April 14, 2015 /PRNewswire/ — The CementBloc has announced the addition of Robin Tzannes, Sharon Howard-Butler, and Marc Law to its creative leadership team. Photo –  Sharon Howard-Butler and Marc Law, formerly of Saatchi & Saatchi Health Sydney, join the agency as SVP, Creative Director, Copy, and VP, Associate Creative Director, Art, respectively. […]

Read More »

REGiMMUNE Announces Collaboration With JDRF and Pfizer Inc. for Type 1 Diabetes Prevention and Treatment Promoting Regulatory T-Cells

Antigen-Specific Immunotherapy to Potentially Prevent or Delay Diabetes in Preclinical Model TOKYO, JAPAN–(Marketwired – Apr 14, 2015) – REGiMMUNE Corporation (RGI) and JDRF today announced a partnership, along with financial assistance and scientific expertise from Pfizer Inc., for a research collaboration to develop an antigen-specific immunotherapy utilizing RGI’s proprietary αGalCer/liposome platform for immunological tolerance for […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom